Navigation Links
Patient Disparities Seen in Lung Cancer Drug Trials

WEDNESDAY, July 6 (HealthDay News) -- Women, older people and minorities are under-represented in lung cancer drug trials in the United States, according to a new study.

Researchers say that this could have a significant impact on the efficacy and safety of new treatments among these groups, particularly the elderly.

"Our results suggest that the trial population used for approval of drugs do not represent well the U.S. population who may receive the marketed agent," the study's principal investigator, Dr. Shakun Malik, a medical officer at the U.S. Food and Drug Administration in Silver Spring, Md., said in a news release.

"This fact is concerning particularly for older patients who may experience greater toxicity when given the same dose and combination of drugs based on testing in a younger population," Malik explained in the release from the International Association for the Study of Lung Cancer.

In conducting the study, which was slated for presentation Wednesday at the 14th World Conference on Lung Cancer in Amsterdam, researchers reviewed 10 years of trial data for the treatment of non-small cell lung cancer submitted to the U.S. Food and Drug Administration.

The study revealed that although 42 percent of patients diagnosed with lung cancer in the United States between 1975 and 2008 were women, only 32 percent of enrollees in 10 national and international drug trials for non-small cell lung cancer between 2000 and 2010 were women.

Moreover, although 73 percent of lung cancer patients in the United States are older than 65, only 36 percent of the drug trial population was in that age group.

Blacks also develop lung cancer at higher rates than whites, but they only comprised 2 percent of trial participants in the 10-year period, the study found. Meanwhile, researchers noted that whites made up 78 percent of enrollees, Asians comprised 15 percent, Hispanics 2 percent and "other" accounted for 2 percent.

Because this study was presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.

More information

The U.S. National Cancer Institute provides more information on lung cancer treatment.

-- Mary Elizabeth Dallas

SOURCE: International Association for the Study of Lung Cancer, news release, July 6, 2011

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Elderly Dutch lung patients survival improved by new treatment options between 2003-2009
2. Patients at small, isolated, rural hospitals in US more likely to receive lower quality of care
3. ALK rearrangement found in nearly 10 percent of patients in Lung Cancer Mutation Consortium
4. Worse outcomes for older breast cancer patients with other health problems
5. Heart transplant patients at risk for serious skin cancers
6. Delaying Intravenous Feeding of ICU Patients May Aid Recovery
7. Research Sheds Light on Cause of Brain Deficits in HIV Patients
8. Patients treated with sunitinib and sorafenib respond to flu vaccine
9. Innovative UBC-BC Cancer Agency system reduces waitlisting for chemotherapy patients
10. Team approach reduces urinary tract infections in rehab patients
11. Intensive, hands-on effort reduces bloodstream infections in critically ill patients
Post Your Comments:
Related Image:
Patient Disparities Seen in Lung Cancer Drug Trials
(Date:11/25/2015)... ... 2015 , ... TyloHelo Inc , North America’s largest ... accessories help improve the bather experience in the sauna, and the accessories selected ... purist looking for simplicity in design to accessories that encourage a greater expression ...
(Date:11/25/2015)... , ... November 25, 2015 , ... For the first ... “ Two Organizations, One Beat ” campaign. The partnership between the two groups began ... aid in MAP International’s cause. , MAP International was founded in 1954 and is ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 25, 2015, ... for the Narconon network, announced the release of a new cutting edge recovery program ... organization has been working with drug- and alcohol-addicted individuals with the purpose to free ...
(Date:11/25/2015)... , ... November 25, 2015 , ... Smiles by ... TMJ Disorder, Bruxism, and moderate facial wrinkling. While many patients are aware of the ... the great success Botox® delivers to those suffering with discomfort, soreness, and pain as ...
(Date:11/25/2015)... ... ... In an ongoing Clinical Study conducted by an independent physician, Andrew Gostine, ... evaluating the efficacy of its product and its disinfection protocol. This study is taking ... 2014 through October 2015 at a 360-bed, acute-care, academic medical center located in Chicago, ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , Nov. 25, 2015 USP ... hazardous drug preparations (e.g. pharmacists, pharmacy technicians, nurses, ... veterinary technicians). The chapter also covers all entities ... (e.g., pharmacies, hospitals, other healthcare institutions, patient treatment ... --> --> What ...
(Date:11/25/2015)... 25, 2015 Asia ... which BioLight and the New Investors will make a ... via a private placement. The financing will help IOPtima ... system used in the treatment of glaucoma, as well ... the IOPtimate™ system with the U.S. Food and Drug ...
(Date:11/25/2015)... LONDON , November 25, 2015 Developmental, ... key role in boosting the profitability of pharmaceutical products, ... Developmental, commercial, and regulatory/legal strategies all play ... says GBI Research . --> ... all play a key role in boosting the profitability of pharmaceutical ...
Breaking Medicine Technology: